---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-24-000032"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:06:44.315827+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics reports Q4 2023 GAAP net loss $36.6M; cash runway extended to Q1 2025 via $100M CEO note amendment

## Summary
- GAAP net loss Q4 2023 $36.6M ($0.05/sh) vs $19.3M ($0.07/sh) a year ago; full-year loss $614.9M primarily from $500M ivonescimab licensing fee.
- Cash and equivalents, restricted cash, and short-term investments $186.2M at Dec 31, 2023, down from $648.6M at Dec 31, 2022.
- Extended cash runway guidance to Q1 2025 from Q3 2024 after amending $100M CEO note to April 1, 2025 maturity with interest rate >12%.
- Actively enrolling two Phase III trials (HARMONi and HARMONi-3) for ivonescimab in NSCLC; HARMONi enrollment completion expected H2 2024.
- Updated Phase II data: 24-month OS rate 64.8% in 1L squamous NSCLC; median OS 22.5 months in 2L+ EGFR-mutant NSCLC.

## SEC filing metadata
- accession: 0001599298-24-000032
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000032/0001599298-24-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000032/smmt-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-24-000032
- JSON: https://secwatch.observer/filing/0001599298-24-000032.json
- Plain text: https://secwatch.observer/filing/0001599298-24-000032.txt

## Key facts
- Earnings Releases
  Summit Therapeutics Inc. updated its the fourth quarter and year ended December 31, 2023 guidance (reaffirmed).
  - Period: the fourth quarter and year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 20, 2024, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000032/0001599298-24-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.